J Pathol Transl Med.  2024 Mar;58(2):87-90. 10.4132/jptm.2023.12.28.

Fibrin-associated large B-cell lymphoma arising in an endovascular graft: first case report in Korea

Affiliations
  • 1Department of Pathology, Dong-A University College of Medicine, Busan, Korea

Abstract

Fibrin-associated large B-cell lymphoma (FA-LBCL) is an extremely rare subtype of LBCL that consists of microscopic aggregates of atypical large B cells in the background of fibrin. Here, we report the first case of FA-LBCL in Korea. A 57-year-old male presented with a large amount of thrombus in the thoracic aorta during follow-up for graft replacement of the thoracoabdominal aorta 8 years prior. The removed thrombus, measuring 4.3 × 3.1 cm, histologically exhibited eosinophilic fibrinous material with several small clusters of atypical lymphoid cells at the periphery. The atypical cells were positive for CD20 by immunohistochemistry and for Epstein-Barr virus by in situ hybridization. The Ki-67 proliferation rate was 85%. The patient was still alive with no recurrence at the 7-year follow-up after thrombectomy. Although the diagnosis can be very difficult and challenging due to its paucicellular features, pathologists should be aware of FALBCL, which has likely been underestimated in routine evaluations of thrombi.

Keyword

Fibrin-associated large B-cell lymphoma; Vascular graft; Thrombus

Figure

  • Fig. 1 Gross finding. The received specimen, measuring 4.3 × 3.1 cm in dimension, is a usual yellowish-brown thrombus with no tumorous lesion on the cut surface.

  • Fig. 2 Histologic, immunohistochemical, and in situ hybridization findings. (A) The histologic section shows abundant acellular eosinophilic fibrinous material with several small viable cellular clusters at the periphery (circled areas). (B) Higher magnification of the arrowed part of (A) shows aggregates of atypical, large lymphocytes. (C) The atypical lymphoid cells reveal vesicular nuclei, irregular nuclear membranes, and frequent mitoses. (D) The atypical cells are positive for CD20. (E) The Ki-67 proliferation rate is 85%. (F) These cells exhibit intense and diffuse positive staining for Epstein-Barr virus–encoded RNA by in situ hybridization.


Reference

References

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: IARC Press;2017.
2. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022; 36:1720–48.
3. WHO Classification of Tumours Editorial Board. WHO classification of tumors: thoracic tumours. 5th ed. Lyon: IARC Press;2021.
4. Miller DV, Firchau DJ, McClure RF, Kurtin PJ, Feldman AL. Epstein-Barr virus-associated diffuse large B-cell lymphoma arising on cardiac prostheses. Am J Surg Pathol. 2010; 34:377–84.
5. Gruver AM, Huba MA, Dogan A, Hsi ED. Fibrin-associated large B-cell lymphoma: part of the spectrum of cardiac lymphomas. Am J Surg Pathol. 2012; 36:1527–37.
6. Boyer DF, McKelvie PA, de Leval L, et al. Fibrin-associated EBV-positive large B-cell lymphoma: an indolent neoplasm with features distinct from diffuse large B-cell lymphoma associated with chronic inflammation. Am J Surg Pathol. 2017; 41:299–312.
7. Di Napoli A, Soma L, Quintanilla-Martinez L, et al. Cavity-based lymphomas: challenges and novel concepts. A report of the 2022 EA4HP/SH lymphoma workshop. Virchows Arch. 2023; 483:299–316.
8. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103:275–82.
9. Loong F, Chan AC, Ho BC, et al. Diffuse large B-cell lymphoma associated with chronic inflammation as an incidental finding and new clinical scenarios. Mod Pathol. 2010; 23:493–501.
Full Text Links
  • JPTM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr